CTHIn ForceLegislation
Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
Part 1Dual labelling name permitted from 1 May 2023 until 30 April 2026
Start here
Get a plain-English read of Part 1
Turn the raw legal text into a practical explanation grounded in Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines.
Part 1—Dual labelling name permitted from 1 May 2023 until 30 April 2026
| Ingredient name |
|---|
| amobarbital (amylobarbitone) |
| amphotericin B (amphotericin) |
| asparaginase (colaspase) |
| calcitonin salmon (salcatonin) |
| dactinomycin (actinomycin D) |
| doxycycline hyclate (hydrochloride) |
| estropipate (piperazine oestrone) |
| formoterol (eformoterol) |
| furosemide (frusemide) |
| glycopyrronium bromide (glycopyrrolate) |
| lidocaine (lignocaine) |
| mecobalamin (co-methylcobalamin) |
| pentoxifylline (oxpentifylline) |
| phenobarbital (phenobarbitone) |
| procaine benzylpenicillin (procaine penicillin) |
| tetracosactide (tetracosactrin) |